8-K: Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results, Provides Business Updates, and Outlines Key Milestones for 2025

Rallybio announces its Q4 and full year 2024 financial results, highlighting progress in clinical trials and providing a financial runway into the second half of 2026.

Summary

• Rallybio reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company's cash, cash equivalents, and marketable securities totaled $65.5 million as of December 31, 2024, which is expected to fund operations into the second half of 2026.
• Key data readouts from the Sentinel participant in the RLYB212 Phase 2 clinical trial are expected in the second and third quarters of 2025.
• Initiation of the RLYB116 confirmatory PK/PD study is expected in the second quarter of 2025, with data anticipated in the second half of 2025.
• Revenue for the fourth quarter of 2024 was $38 thousand, and $0.6 million for the full year, compared to no revenue in the same periods in 2023.
• Research and Development (R&D) expenses were $7.4 million for the fourth quarter of 2024 and $41.5 million for the full year, compared to $15.9 million and $53.5 million, respectively, in 2023.
• General & Administrative (G&A) expenses were $4.3 million for the fourth quarter of 2024 and $19.6 million for the full year, compared to $5.2 million and $25.4 million, respectively, in 2023.
• Rallybio reported a net loss of $11.0 million, or $0.25 per common share, for the fourth quarter of 2024, compared to a net loss of $20.2 million, or $0.50 per common share, for the same period in 2023.
• The net loss for the year ended December 31, 2024, was $57.8 million, or $1.33 per common share, compared to a net loss of $74.6 million, or $1.84 per common share, for the year ended December 31, 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the improved financial results, strong cash position, and progress in clinical programs. However, the company is still operating at a loss, which tempers the overall sentiment.

Positives

• Rallybio has a strong cash position of $65.5 million, providing a runway into the second half of 2026.
• The company is progressing its clinical programs, with key data readouts expected for RLYB212 and the initiation of a confirmatory study for RLYB116 in 2025.
• Revenue increased due to the collaboration agreement with Johnson & Johnson.
• R&D and G&A expenses decreased, contributing to a lower net loss compared to the previous year.

Negatives

• The company reported a net loss of $57.8 million for the year ended December 31, 2024, although this is an improvement from the previous year's $74.6 million loss.
• Revenue remains relatively low at $0.6 million for the year ended December 31, 2024.

Risks

• The company's success depends on the successful initiation, conduct, and completion of clinical trials, including the RLYB116 confirmatory PK/PD study and the Phase 2 trial for RLYB212.
• Rallybio's ability to fund operations depends on its cash resources and ability to raise additional capital.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The forward-looking statements are subject to risks and uncertainties described in Rallybio's filings with the SEC.

Future Outlook

Rallybio expects its current cash resources to be sufficient to fund operations into the second half of 2026 and anticipates key data readouts and study initiations in 2025 and 2026.

Management Comments

• 'We are pleased with our strong execution in 2024, and look forward to reporting on our planned milestones in 2025,' said Stephen Uden, M.D., Chief Executive Officer of Rallybio.
• Management is laser focused on driving value for Rallybio in 2025 and positioning the Company for sustained growth and success in the future through exceptional execution of programs and continued financial discipline.

Industry Context

Rallybio is focused on developing therapies for rare diseases, a sector that has seen increasing investment and attention due to unmet medical needs and potential for orphan drug designations. The company's pipeline targets areas such as maternal fetal health, complement dysregulation, hematology, and metabolic disorders, aligning with current trends in biotechnology and pharmaceutical research.

Comparison to Industry Standards

• Rallybio's cash runway into the second half of 2026 is a positive sign, as many biotech companies of similar size need to raise capital more frequently.
• Companies like Alexion Pharmaceuticals (now part of AstraZeneca) and BioCryst Pharmaceuticals are key players in the complement-mediated disease space, and Rallybio's RLYB116 program aims to compete in this area.
• The development of REV102 for hypophosphatasia puts Rallybio in competition with companies like Enzyvant, which are also developing therapies for rare metabolic disorders.
• The decrease in R&D expenses reflects a trend among some biotech companies to streamline operations and focus on key programs.

Stakeholder Impact

• Shareholders: The announcement provides updates on financial performance and clinical development, which could influence investor confidence.
• Employees: The company's financial stability and progress in clinical programs could impact employee morale and job security.
• Patients: Progress in developing therapies for rare diseases could offer hope for improved treatment options.
• Partners: The collaboration with Johnson & Johnson is a key partnership that contributes to revenue and program development.

Next Steps

• Report preliminary PK and safety data for the sentinel participant in the RLYB212 Phase 2 trial.
• Present interim data from the FNAIT natural history study.
• Initiate the RLYB116 confirmatory PK/PD study.
• Advance REV102 into IND-enabling studies to support a Phase 1 study in 2026.
• Present data evaluating REV102 in a preclinical model of later-onset HPP.

Key Dates